ClinicalTrials.gg
RecruitingNCT05981950Updated Aug 8, 2023

Real-world of AI in Diagnosing Retinal Diseases

An observational study in Artificial Intelligence and Retinal Diseases, sponsored by Beijing Tongren Hospital. Recruiting at 1 site in China. Open to participants aged 1 Year to 100 Years. Per ClinicalTrials.gov, last updated 2023-08-08.

Sponsored by Beijing Tongren Hospital · Observational

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100,000
Ages
1 Year to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Retinal Diseases with a site in China — 12 open to participants now, 14 under way, 1 of them phase 3. Retinal Diseases · China.

Planned enrollment
2nd of 17
100,000 · median 2,000
Started
2023
with 2 others
Observational
17 of 29
7 open now
Primary completion
2028-08
later than 11 of 13 live
Registered
18th of 29
by date
Lead sponsor
4 of 29
Beijing Tongren Hospital

Among the 29 studies in Retinal Diseases with a site in China, this one is the 2nd largest by planned enrollment of the 17 observational ones that give a count, is one of 3 that started in 2023, is one of 17 observational ones, reaches primary completion later than 11 of the 13 other live ones, and was the 18th registered.

Retinal Diseases

333 studies on the registry are indexed under Retinal Diseases; 59 are open to participants now.

Browse Retinal Diseases studies →

Open to participants now

12 of the 29 studies in Retinal Diseases with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Retinal Diseases studies recruiting now, 30 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 16 take children under 18; 19 take healthy volunteers.

This study: 1 Year to 100 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Retinal Diseases with a site in China, or all of them as a file.
02

Study summary

The objective of this study is to apply an artificial intelligence algorithm to diagnose multi-retinal diseases in real-world settings. The effectiveness and accuracy of this algorithm are evaluated by sensitivity, specificity, positive predictive value, negative predictive value, and area under curve.

Read the detailed description

The objective of this study is to apply an artificial intelligence algorithm to diagnose referral diabetes retinopathy, referral age-related macular degeneration, referral possible glaucoma, pathological myopia, retinal vein occlusion, macular hole, macular epiretinal membrane, hypertensive retinopathy, myelinated fibers, retinitis pigmentosa and other retinal lesions from fundus photography. tic 45-degree fundus cameras, trained operators took binocular fundus photography on participants. Operators were then asked to identify gradable images and unload for algorithm diagnosis. The effectiveness and accuracy of this algorithm are evaluated by sensitivity, specificity, positive predictive value, negative predictive value, area under curve, and F1 score.

03

Conditions studied

  • Artificial Intelligence
  • Retinal Diseases

Browse trials for

04

Who can participate

Ages eligible
1 Year to 100 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population is derived from an anonymous database that contains health examination results of the general population.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • fundus photography around 45° field which covers optic disc and macula
  • complete identification information

Exclusion criteria

Exclusion Criteria:

  • insufficient information for diagnosis
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retinal diseases diagnosed by artificial intelligence algorithm

    An artificial intelligence algorithm was applied to diagnose referral diabetes retinopathy, referral age-related macular degeneration, referral possible glaucoma, pathological myopia, retinal vein occlusion, macular hole, macular epiretinal membrane, hypertensive retinopathy, myelinated fibers, retinitis pigmentosa and other retinal lesions from fundus photography.

    Diagnostic Test: artificial intelligence algorithm

Interventions

  • Diagnostic testartificial intelligence algorithm

    Retinal diseases diagnosed by artificial intelligence algorithm

06

What researchers measure

Primary outcomes

  1. Area under curve

    We used the receiver operating characteristic (ROC) curve and area under curve to examine the ability of this artificial intelligence algorism recognition and classification of retinal diseases.

    Time frame: 1 month

  2. Sensitivity and specificity

    We used sensitivity and specificity to examine the ability of this artificial intelligence algorism recognition and classification of retinal diseases.

    Time frame: 1 month

  3. Positive predictive value, negative predictive value

    We used positive predictive value and negative predictive value to examine the ability of this artificial intelligence algorism recognition and classification of retinal diseases.

    Time frame: 1 month

  4. F1 score

    We used F1 score to examine the ability of this artificial intelligence algorism recognition and classification of retinal diseases.

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
  • Wen-Bin Wei
    Beijing, Beijing 100730, China
    Recruiting
    • Wen-Bin Wei, MD · Contactweiwenbintr@163.com · 58269516
    • Wen-Bin Wei, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Aug 2028, 60 months after the start.

Of 54 observational studies under Retinal Diseases, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 17. This study's planned 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2023
First posted
Aug 8, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Aug 1, 2028
CompletionEst.
Aug 1, 2029
Last update
Aug 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05981950
Responsible party
Wenbin Wei (Prof, Beijing Tongren Hospital) — Principal investigator
First posted
Aug 8, 2023
Start date
Aug 1, 2023
Primary completion
Aug 1, 2028 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Aug 8, 2023

Study contacts

Wenbin Wei, MD
Contact
weiwenbintr@163.cim
58269516
Ruiheng Zhang, MD
Contact
zhangruihengsy@outlook.com
18801121782

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion